The resolution means that the agreement with Atlas Special Opportunities, LLC regarding convertibles amounting to MSEK 55 with attached warrants, which was made public on 20 December 2022, will be fulfilled in accordance with its terms and conditions.
“AegirBio has been informed that the Disciplinary Committee of Nasdaq Stockholm has resolved to not delist AegirBio and instead order the company to pay fees. In our opinion, it is the correct resolution to not comply with Nasdaq Stockholm’s request for delisting. The company is hereby putting a highly turbulent time behind it and is looking forward to focusing on its core business”, says Bradley Messmer, CEO of AegirBio.
Aegirbio is a Swedish diagnostics company offering tests to monitor and optimize the dosing of biological drugs by means of a unique, patented technology platform. Biological therapies is the fastest growing segment of the pharmaceutical industry; a quarter of all drugs are projected to be biological in 2020. At the same time, drug concentrations vary tremendously (up to 100 times) in patients that receive biological drugs in standard doses.
The result of this one size fits all-approach is that patients with low drug concentrations do not respond to treatment while excessive drug concentrations increase the risk of adverse effects in others. The uncertainty surrounding dosing results in overdosing or underdosing in about 55 percent of the cases, which causes unnecessary costs and suboptimal clinical outcomes.
The Company's tests for optimal dosing of biological drugs will be focused on neurological disorders, autoimmune diseases and cancer. In the first quarter of 2020, Aegirbio initiated sales in the U.S. of the MoNATor test for the drug Tysabri, which is used for treatment of the neurological disorder Multiple Sclerosis (MS). Aegirbio’s goal is to launch a total of four tests before 2023. Diagnostics will be offered through laboratory testing as well as in the form of a P.O.C. (Point of Care) test for use in hospitals and health centres. The plan further includes P.O.N. (Point of Need) tests for use at home.
For more information, see Aegirbio's website www.aegirbio.com
The company's Certified Adviser is Eminova Fondkomission AB | 08-684 211 00 | email@example.com
This information is such information that Aegirbio AB is obliged to publish in accordance with the EU Market Abuse Regulation.